When did 4D Molecular Therapeutics report Q4 2024 earnings?

4D Molecular Therapeutics (FDMT) reported Q4 2024 earnings on February 28, 2025 before market open.

What were 4D Molecular Therapeutics's Q4 2024 revenue and EPS?

4D Molecular Therapeutics reported revenue of $1.0K and eps of $-0.90 for Q4 2024.

Did 4D Molecular Therapeutics beat estimates in Q4 2024?

Revenue missed the consensus estimate of $2.3M by $2.3M. EPS missed the consensus estimate of $-0.80 by $0.10.

Where can I find 4D Molecular Therapeutics's Q4 2024 SEC filings?

You can read the 10-K periodic report (0000950170-25-030056) directly on SEC EDGAR. The filing index links above go to sec.gov.

4D Molecular Therapeutics FDMT Q4 2024 Annual earnings

Reported February 28, 2025 · Before market open

Revenue$1.0KMiss by $2.3M

EPS-$0.90Miss by $0.10

Revenue estimate$2.3M

EPS estimate-$0.80

Next report

Aug 10, 2026 (In 1 week)

Revenue estimate$3.7M

EPS estimate-$1.04

Financials

Q4 2024

Income statement

See full

Revenue$1.0K—

Operating income-$56.1M-53.1%

Net income-$49.7M-53.9%

EPS (diluted)-$0.90-16.9%

Balance sheet

See full

Cash & equivalents$149.3M-40.1%

Total debt$24.6M+67.7%

Total equity$510.6M+65.9%

Total assets$560.4M+64.9%

Cash flow

See full

Operating cash flow-$45.9M-86.1%

CapEx$949.0K+72.9%

Free cash flow-$46.8M-85.8%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$257.49M-67.5%

Enterprise value$132.76M-76.2%

P/S6,959.1×+6,921×

Profitability

See full

Operating margin-507,678.4%-508,224pp

Net margin-434,778.4%-435,266pp

FCF margin-373,975.7%-374,355pp

Returns & leverage

See full

Return on equity-39.3%+2.1pp

Debt / equity0×0.0×

Current ratio14.9×-0.7×

Segments

By product

See full

Collaboration And License Revenue$1.0K—

Versus estimates

Revenue

Q1 2026$3.0MBeat by $459.5K Q4 2025$85.1MBeat by $58.1M Q3 2025$90.0KMiss by $30.8M Q2 2025$15.0KBeat by $10.3K Q1 2025$14.0KMiss by $523.5K

Q4 2024$1.0KMiss by $2.3M

Diluted EPS

Q1 2026-$1.01Miss by $0.04 Q4 2025$0.43Beat by $0.96 Q3 2025-$1.01Beat by $0.01 Q2 2025-$0.98Miss by $0.10 Q1 2025-$0.86Miss by $0.02

Q4 2024-$0.90Miss by $0.10

Ask the moment 4D Molecular Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did 4D Molecular Therapeutics report Q4 2024 earnings?: 4D Molecular Therapeutics (FDMT) reported Q4 2024 earnings on February 28, 2025 before market open.
What were 4D Molecular Therapeutics's Q4 2024 revenue and EPS?: 4D Molecular Therapeutics reported revenue of $1.0K and eps of $-0.90 for Q4 2024.
Did 4D Molecular Therapeutics beat estimates in Q4 2024?: Revenue missed the consensus estimate of $2.3M by $2.3M. EPS missed the consensus estimate of $-0.80 by $0.10.
Where can I find 4D Molecular Therapeutics's Q4 2024 SEC filings?: You can read the 10-K periodic report (0000950170-25-030056) directly on SEC EDGAR. The filing index links above go to sec.gov.